III. Antagonist's viewpoint

[1]  J. Cohn,et al.  Prognosis of congestive heart failure and predictors of mortality. , 1988, The American journal of cardiology.

[2]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[3]  W. S. Ring,et al.  Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failure. , 1987, The American journal of cardiology.

[4]  J. Cohn,et al.  Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. , 1987, American heart journal.

[5]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[6]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[7]  M. Packer,et al.  Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[8]  B. W. East,et al.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. , 1985, British heart journal.

[9]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[10]  J. Cohn,et al.  Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[11]  J. Cohn,et al.  Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[12]  J. Cohn,et al.  Regional blood flow response to orthostasis in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[13]  J. Cohn,et al.  The Neurohumoral and Hemodynamic Response to Orthostatic Tilt in Patients with Congestive Heart Failure , 1983, Circulation.

[14]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[15]  J. Cohn,et al.  Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.

[16]  J. Cohn,et al.  Acute and Long‐term Response to an Oral Converting‐enzyme Inhibitor, Captopril, in Congestive Heart Failure , 1980, Circulation.

[17]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[18]  J. Cohn,et al.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. , 1978, Chest.

[19]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[20]  J. Cohn.  Vasodilator Therapy for Heart Failure: The Influence of Impedance on Left Ventricular Performance , 1973, Circulation.

[21]  B. Zimmerman,et al.  Pattern of renal vasoconstriction and transmitter release during sympathetic stimulation in presence of angiotensin and cocaine. , 1968, The Journal of pharmacology and experimental therapeutics.